Chan T M, Cheng I K, Tam S C
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Nephron. 1994;67(3):317-21. doi: 10.1159/000187986.
Thirty-eight renal allograft recipients who had persistent hyperlipidemia and stable renal function 27.8 +/- 18.2 months after renal transplantation were treated with gemfibrozil. Gemfibrozil therapy resulted in a decrease in the levels of total cholesterol (TC; 297.6 +/- 41.0 mg/dl to 249.2 +/- 43.7 mg/dl, -16.3%; p < 0.0001), triglyceride (TG; 231.9 +/- 116.8 to 125.7 +/- 58.4 mg/dl, -45.8%, p < 0.0005), and LDL-cholesterol (LDL-C; 203.8 +/- 37.4 to 174.5 +/- 42.5 mg/dl, -14.4%; p = 0.001), which were sustained for 29.1 +/- 16.0 months. Comparison of sequential lipid profiles between gemfibrozil-treated individuals and untreated hyperlipidemic controls matched for age, sex, time after transplantation, and the degree of hyperlipidemia, showed that gemfibrozil-treated patients had lower levels of TC (239.9 +/- 39.5 vs. 272.8 +/- 34.1 mg/dl; p < 0.005), TG (125.7 +/- 26.6 vs. 167.3 +/- 69.0 mg/dl; p < 0.05), and LDL-C (160.2 +/- 41.3 vs. 185.3 +/- 26.6 mg/dl; p < 0.05) on serial follow-up. No significant side-effect was observed with gemfibrozil therapy. Our data showed that gemfibrozil was a safe and effective drug for the treatment of hyperlipidemia in renal allograft recipients, which could reduce these patients's long-term cardiovascular risks.
38名肾移植受者在肾移植后27.8±18.2个月出现持续性高脂血症且肾功能稳定，接受了吉非贝齐治疗。吉非贝齐治疗使总胆固醇（TC；从297.6±41.0mg/dl降至249.2±43.7mg/dl，-16.3%；p<0.0001）、甘油三酯（TG；从231.9±116.8降至125.7±58.4mg/dl，-45.8%，p<0.0005）和低密度脂蛋白胆固醇（LDL-C；从203.8±37.4降至174.5±42.5mg/dl，-14.4%；p = 0.001）水平降低，且这些降低持续了29.1±16.0个月。对吉非贝齐治疗的个体与年龄、性别、移植后时间和高脂血症程度相匹配的未治疗高脂血症对照者的连续血脂谱进行比较，结果显示，连续随访时，接受吉非贝齐治疗的患者的TC（239.9±39.5 vs. 272.8±34.1mg/dl；p<0.005）、TG（125.7±26.6 vs. 167.3±69.0mg/dl；p<0.05）和LDL-C（160.2±41.3 vs. 185.3±26.6mg/dl；p<0.05）水平较低。未观察到吉非贝齐治疗有明显副作用。我们的数据表明，吉非贝齐是治疗肾移植受者高脂血症的一种安全有效的药物，可降低这些患者的长期心血管风险。
